Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

High-Throughput Microarrayer

By Drug Discovery Trends Editor | June 5, 2012

CapitalBio Corporation, a leading developer and manufacturer of microarray systems, is introducing its microarray instruments to the US market. CapitalBio has signed on Core Life Sciences as its newest distributor to market and sell its range of microarray spotters, scanners, substrates, and reagents in the United States.

CapitalBio has developed a microarray platform that stands apart from other manufacturers’ systems in the versatility, precision, and durability offered at its particular price point. CapitalBio’s microarrayers offer both contact and proprietary non-contact array printing capabilities, available three year extended warranties, with print repeatability equal to or better than competing arrayers—but at a fraction of the competition’s price.

CapitalBio’s line of microarrayers includes high, medium, and low throughput arrayers. The SmartArrayer 136 is CapitalBio’s highest throughput arrayer with a capacity of 136 microarray slides or 16 96-well plates. The SmartArrayer comes equipped with precise, high speed mechanics, with print repeatability at ±3 μm and print head velocity at 300 mm/sec. The Personalarrayer 16, CapitalBio’s benchtop microarrayer, has a capacity of 16 microarray slides or two 96-well plates and a print repeatability of  less than 10 μm.

Both CapitalBio’s SmartArrayer and PersonalArrayer instruments feature CapitalBio’s proprietary Microdispense non-contact array printing technology, which uses an advanced pneumatic system. Other non-contact dispensing microarrayers typically use one syringe pump per dispensing channel. This design means increased maintenance costs as well as higher incremental costs for adding more channels, because each additional channel requires another syringe pump. CapitalBio’s Microdispense technology, on the other hand, allows for expansion to up to 4 channels (in the SmartArrayer platform) without requiring any additional compressors or pumps. (Only the additional  print heads need to be added and a small manifold changed).  

Given the viscosity of protein samples, Microdispense technology is best suited for protein array production, while contact printing is best suited for oligonucleotide arrays.

CapitalBio Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE